Eisai   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Saitama Japan (1955)
Status: Acquired by Sarepta Therapeutics (2014)

Organization Overview

First Clinical Trial
1995
NCT00050999
First Marketed Drug
1990
altretamine (hexalen)
First NDA Approval
1996
donepezil (aricept)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Clinical Research Center, Eisai, Co., Ltd | Drug Fostering and evolution Coodination Department, Corporate Regulattory Compliance, Safety and Quality Assurance Headquaters, Eisai Co., Ltd., Japan | Drug Fostering and Evolution Coordination Department, Corporate Medical Affairs Headquarters, Eisai Co., Ltd. | Drug Fostering and Evolution Coordination Department, Corporate Regulatory Compliance, Safety and Quality Assurance Headquarters, Eisai Co., Ltd. | Drug Fostering and Evolution Coordination Department, Eisai Co., Ltd. | Drug Fostering and Evolution Cordination Department, Eisai Co., Ltd. | Eisai Asia Regional Services Ltd. | Eisai China Inc. | Eisai Co., Ltd. | Eisai Co., Ltd - Development Clinical Research Department. Clinical Research Center | Eisai Co., Ltd - Development Clinical Research Dept., Clinical Research Center | Eisai Company Lmited | Eisai Farmaceutica, S.A. | EISAI Farmaceutica S.A. Head of Medical Department | Eisai France | Eisai Global Clinical Development | Eisai Global Study Director | Eisai GmbH | Eisai GmbH, Frankfurt, Germany | Eisai Inc. | EISAI INC | Eisai Korea | Eisai Korea Inc. | Eisai Limited | Eisai Limted | EISAI MEDCL RES | Eisai Medical Research (formerly MGI Pharma Inc.) | Eisai Medical Services | Eisai/Morphotek | Eisai Pharmaceuticals India Private limited | Eisai Pharmaceuticals India Pvt. Ltd | Eisai Research Institute | Eisai Taiwan | Frontier Product Creation Unit, Eisai Product Creation Systems | General Manager - Medical and Regulatory Affairs, Eisai Pharmaceuticals India Private Limited | General Manager Medical & Regulatory Affairs, Eisai Pharmaceuticals India Private Limited, Mumbai, MS, India | H3 Biomedicine Inc. | JAC PCU Eisai Co., Ltd. | JAC PCU. EPCS, Eisai Co., Ltd. | Japan/Asia Clinical Research Product Creation Unit | Japan/Asia Clinical Research Product Creation Unit, Eisai Co., Ltd. | Japan/Asia Clinical Research Product Creation Unit, Japan Clinical Development, Japan Clinical Development Section | Japan Clinical Pharmacology, Eisai Co., Ltd. | KAN Clinical Development Section, JAPAN/ASIA Clinical Research Product Creation Unit, Eisai Product Creation System | Medical Affairs Department , Eisai Taiwan Inc. | Medical Affairs, Eisai, Inc | Medical Department, Eisai Korea Inc. | Neuroscience Cliical Development Section, Japan /Asia Clinical Research PCU | Neuroscience Clinical Development Section. JAC PCU | Neuroscience Clinical Development Section. JAC PCU. Eisai Co., Ltd. | Neuroscience Clinical Development Section, Japan/Asia Clinical Research Product Creation Unit, Eisai Co., Ltd. | Neuroscience Clinical Development Section, Japan/Asia Clinical Research Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd. | Neurosciences Clinical Development Section, Japan / Asia Clinical Research, Product Creation Unit, Eisai Product Creation System. | New Drug Development Department, Eisai Company Limited | New Product Development, Clinical Research Center, Eisai Co., Ltd. | Oncology Clinical Development Section. JAC PCU. Eisai Co., Ltd. | Oncology Clinical Development Section. JAC PCU., Eisai, Co., Ltd | Oncology Clinical Development Section, Japan / Asia Clinical Research, Product Creation Unit, Eisai Product Creation System | Post -marketing Clinical Research Department, Clinical Research Center - Eisai Company Limited